Who Exports Pravastatin from India — 20 Suppliers Behind a $31.2M Market
India's pravastatin export market is supplied by 20 active exporters who collectively shipped $31.2M across 634 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 24.4% market share, followed by GLENMARK PHARMACEUTICALS LIMITED and MYLAN LABORATORIES LIMITED. The top 5 suppliers together control 92.8% of total export value, reflecting a concentrated market structure.
Top Pravastatin Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading pravastatin exporter from India, holding a 24.4% share of the $31.2M market across 634 shipments from 20 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, GLENMARK PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, MEDREICH LIMITED, STRIDES PHARMA SCIENCE LIMITED — collectively control 92.8% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (24.4%), GLENMARK PHARMACEUTICALS LIMITED (24.0%), MYLAN LABORATORIES LIMITED (22.9%), MEDREICH LIMITED (13.9%), STRIDES PHARMA SCIENCE LIMITED (7.5%).
Top Pravastatin Exporters from India
Ranked by export value · 20 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED PHARMA DRUGS AND MEDI PRAVASTATIN SODIUMAPO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VL4145PH.DRU.& MED.: PRAVACOR 20MG TABLETS [10X10T PER PACK] | $7.6M | 9 | 24.4% |
| 2 | GLENMARK PHARMACEUTICALS LIMITED PRAVASTATIN SOD TAB 40MG 500PHARMACEUTICALS-PRAVASTATIN SOD TAB 40MG500PHARMACEUTICALS PRAVASTATIN SOD TAB 40MG500 CPL | $7.5M | 1 | 24.0% |
| 3 | MYLAN LABORATORIES LIMITED HARMLESS MEDICINES, PRAVASTATIN SODIUM TABLETS 10 MGPRAVASTATIN SODIUM TABLETS 40 MG PACKS 2500S BSPAPX-PRAVASTATIN APX-PRAVASTATIN TABLETS | $7.2M | 2 | 22.9% |
| 4 | MEDREICH LIMITED PRAVASTATIN SODIUM 10MG TABLETS, PO NO.MPRAVASTATIN SODIUM 10MG TABLETS PO NO.MPRAVASTATIN 10MGTABS 40000S-NN-NISSIN/JA | $4.3M | 1 | 13.9% |
| 5 | STRIDES PHARMA SCIENCE LIMITED APX-PRAVASTATIN APX-PRAVASTATIN TABLETSLIPOSTAT 20MG PRAVASTATIN TABLETS 20MG 3PRAVACHOL 20MG PRAVASTATIN TABLETS 20MG | $2.3M | 1 | 7.5% |
| 6 | EMCURE PHARMACEUTICALS LIMITED APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VL4145APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VK9680 | $608.6K | 1 | 2.0% |
| 7 | APOTEX RESEARCH PRIVATE LIMITED APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VL4145APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VK9680 | $409.3K | 1 | 1.3% |
| 8 | VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED PRAVASTATINE ZENTIVA 20 MG TABLETSPRAVASTATINE ZENTIVA 40 MG TABLETSPRAVASTATINE ZYDUS 20 MG TABLETS PRAVAS | $271.5K | 1 | 0.9% |
| 9 | APNAR PHARMA PRIVATE LIMITED PRAVASTATIN SOD TAB 40MG 500PHARMACEUTICALS-PRAVASTATIN SOD TAB 40MG500PHARMACEUTICALS PRAVASTATIN SOD TAB 40MG500 CPL | $185.7K | 1 | 0.6% |
| 10 | SHARON BIO-MEDICINE LIMITED APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VL4145APO PRAVASTATIN 40 MG TAB 100 BTL 41792 771313139526 VK9680 | $168.3K | 1 | 0.5% |
| 11 | TORRENT PHARMACEUTICALS LTD OTHER-PRAVASTATIN HEUMANN 40MG TABLETTENOTHER- PRAVASTATIN HEUMANN 20MG TABLETTEOTHER-PRAVASTATIN HEUMANN 10MG TABLETTEN | $149.3K | 1 | 0.5% |
| 12 | ZYDUS LIFESCIENCES LIMITED PRAVASTATINE ZENTIVA 20 MG TABLETSPRAVASTATINE ZENTIVA 40 MG TABLETSPRAVASTATINE ZYDUS 20 MG TABLETS PRAVAS | $101.5K | 1 | 0.3% |
| 13 | AUROBINDO PHARMA LIMITED PRAVASTATIN TABLETS 10 MG 28'S PACK | $61.4K | 3 | 0.2% |
| 14 | CADILA HEALTHCARE LIMITED PRAVASTATINE ZENTIVA 20 MG TABLETSPRAVASTATINE ZENTIVA 40 MG TABLETSPRAVASTATINE ZYDUS 20 MG TABLETS PRAVAS | $54.6K | 1 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Pravastatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter (November | Yes (April 2007) | Yes | Not verified | Received FDA warning letter in November 2023 for CGMP violations at Matoda - San |
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | Received FDA warning letter in July 2025 for inadequate cleaning and drug testin |
| Emcure Pharmaceuticals Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | Received FDA warning letter in August 2019 for CGMP violations at Hinjawadi faci |
| Strides Pharma Science Limited | Approved | Unknown | Unknown | Not verified | Listed among FDA-approved pharmaceutical plants in India. |
| Mylan Laboratories Limited | Approved | Unknown | Unknown | Not verified | Approved under India's PLI Scheme for Pharmaceuticals as of September 2022. |
| Cadila Healthcare Limited | Approved | Unknown | Unknown | Not verified | Approved under India's PLI Scheme for Pharmaceuticals as of September 2022. |
| Aurobindo Pharma Limited | Approved | Unknown | Unknown | Not verified | Approved under India's PLI Scheme for Pharmaceuticals as of September 2022. |
| Torrent Pharmaceuticals Limited | Approved | Unknown | Unknown | Not verified | Approved under India's PLI Scheme for Pharmaceuticals as of September 2022. |
TransData Nexus reviewed the regulatory standing of 8 leading Pravastatin exporters from India. 5 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 1 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Pravastatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust infrastructure that includes numerous bulk drug manufacturers and a skilled workforce. The city's pharmaceutical sector is further bolstered by the Hyderabad Pharma City project, recognized as a National Investment Manufacturing Zone (NIMZ) and a Project of National Importance. This initiative aims to enhance Hyderabad's capacity in bulk drug manufacturing, potentially impacting the production of active pharmaceutical ingredients (APIs) like Pravastatin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Vadodara, in particular, hosts numerous pharmaceutical companies specializing in the production of finished dosage forms. This region's emphasis on formulations complements the bulk drug production capabilities of other clusters, facilitating a seamless supply chain for medications such as Pravastatin.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical products. Mumbai's strategic location and well-developed port infrastructure enable efficient distribution of pharmaceuticals to international markets. This logistical advantage is crucial for the export of Pravastatin, ensuring timely delivery to key destinations such as the United States, Canada, Hungary, Japan, and Australia.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives. These incentives have attracted numerous pharmaceutical companies, contributing to the region's growth in drug production. While primarily known for manufacturing, the region's role in the Pravastatin supply chain would depend on the presence of specific production facilities for this medication.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 92.8% of Pravastatin shipments, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a few sources.
- Leverage Regional Specializations: Utilize Hyderabad's bulk drug manufacturing capabilities for API procurement and Ahmedabad-Vadodara's expertise in formulations to optimize the production process.
- Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to ensure efficient and timely delivery of Pravastatin to international markets.
- Monitor Regulatory Compliance: Stay informed about regulatory changes and compliance requirements in key export destinations to maintain market access and avoid potential disruptions.
By strategically engaging with these pharmaceutical clusters and adhering to the outlined recommendations, TransData Nexus can enhance its supply chain resilience and efficiency in the Pravastatin market.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Pravastatin exporters from India
Glenmark Pharmaceuticals Limited — Glenmark receives FDA warning for manufacturing violations
In July 2025, the U.S. Food and Drug Administration (FDA) issued a warning letter to Glenmark Pharmaceuticals following an inspection of their Madhya Pradesh facility in February 2025. The inspection revealed issues with cleaning and drug testing procedures, indicating inadequate management oversight and control over drug manufacturing. - IMPACT: Potential disruptions in Pravastatin production and exports due to regulatory scrutiny.
Impact: Potential disruptions in Pravastatin production and exports due to regulatory scrutiny.
Common Questions — Pravastatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which pravastatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 122 recorded shipments worth $7.6M. GLENMARK PHARMACEUTICALS LIMITED (112 shipments) and MYLAN LABORATORIES LIMITED (37 shipments) are also established high-volume exporters.
Q How many pravastatin manufacturers are there in India?
India has 20 active pravastatin exporters with a combined export market of $31.2M across 634 shipments to 17 countries. The top 5 suppliers hold 92.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for pravastatin from India?
Average FOB unit price: $259.20 per unit, ranging from $0.01 to $6146.01. Average shipment value: $49.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 20 verified Indian exporters of Pravastatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 634 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 17 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
634 Verified Shipments
20 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists